Radiation Cystitis After Pelvic RT: HBOT as a Durable, Tissue-Directed Therapy

HBOT supports neovascularization in radiation-injured bladder tissue; earlier referral (particularly for bleeding) may improve response.

Clinical overview: late radiation injury to bladder/urethra

Radiation cystitis reflects late radiation injury to bladder and peri-vesical tissues following pelvic RT. As described by Dr. Anthony Bielawski (wound care and hyperbaric medicine), the underlying pathophysiology is consistent with radiation-induced inflammation with ischemic tissue compromise — functionally analogous to an internal, poorly perfused wound. Reduced microvascular supply contributes to mucosal friability, hematuria, pain syndromes, and irritative lower urinary tract symptoms (LUTS).

At-risk populations include patients treated with pelvic RT — commonly prostate malignancy, but also gynecologic and colorectal cancers. Risk appears higher with higher cumulative dose and external beam radiation, though individual susceptibility remains difficult to predict. The interview cites an incidence of ~10% in pelvic RT recipients (potentially higher in some cohorts).

Symptom profile and impact

Patients may present with:

• Hematuria (including gross hematuria)

• Irritative LUTS: frequency, urgency, nocturia

• Dysuria/pelvic pain, sometimes severe and life-limiting
Dr. Bielawski also notes associated morbidity in advanced disease courses (e.g., recurrent hospitalizations, transfusions) in patients referred after failure of other urologic interventions.

Referral guidance: who should be evaluated for HBOT

Consider referral for HBOT evaluation in patients with confirmed or suspected radiation cystitis who have:

• Recurrent or persistent hematuria, particularly gross hematuria

• Severe LUTS or pain with major quality-of-life impairment

• Refractory symptoms after prior conservative or urologic interventions

According to Dr. Bielawski, HBOT effectiveness for bleeding is described as higher when initiated within ~6 months of symptom onset, though benefit may still occur in chronic or refractory cases — even years into symptom history.

Recommended workup prior to initiation

The interview underscores value of upstream evaluation, typically via urology, including:

• Cystoscopy to confirm characteristic mucosal changes or lesions

• Exclusion of confounders: urinary tract infection, stones, and malignancy recurrence

Patients can be referred even if workup is incomplete; the hyperbaric team can assist in navigating prerequisites, but having cystoscopy and exclusion of alternate etiologies accelerates initiation.

HBOT protocol and expected treatment course

Typical course for radiation cystitis (per interview):

• 30–40 sessions (~6–8 weeks)

• Delivered Monday–Friday

• Approximately 90 minutes at treatment depth, plus compression and decompression

• Severe cases may warrant extended courses; example case required ~60 treatments with complete symptom resolution

Response trajectory: Patients are counseled that symptom improvement may be limited in the first ~20 sessions, consistent with gradual biologic remodeling rather than immediate symptomatic relief.

Mechanism and durability

HBOT supports neovascularization with development of new capillaries and microvasculature in radiation-injured tissues, improving oxygenation and structural integrity. This is framed as a durable therapy rather than a temporizing measure.

Outcomes cited in interview:

• Approximately two-thirds near-complete symptom resolution

• 88–97% good or above-average symptom improvement

Program capability snapshot

The hyperbaric program at Adventist Health Glendale includes:

• Two chambers, each capable of treating two patients simultaneously (up to four patients at a time)

• Flexibility for supine or seated positioning

• Established program infrastructure, with treatment delivered under a hyperbaric-certified physician experienced in radiation injury indications
(These operational details are useful when counseling patients on access, comfort, and throughput.)